Mark Jacobson, MD

Professor

Dr. Jacobson is a clinician, educator, and researcher who has specialized in HIV/AIDS and its complications since joining the UCSF faculty in 1986. His earlier career involved leading multicenter, interventional trials that focused on developing effective treatments for AIDS-associated opportunistic infections. His subsequent research was translational, investigating protective immunity against chronic viral infections, in particular cytomegalovirus (CMV), HIV, and human papillomavirus (HPV). He now teaches medicine residents and medical students, provides clinical care and directs urgent care medical services for the Ward 86 HIV clinic at San Francisco General Hospital, and is the editor for the Ward 86 Medical Management Recommendations posted on UCSF’s HIV InSite website. Dr. Jacobson is also the author of Sensing Light, a novel about the unfolding of the AIDS epidemic in 1980s San Francisco from the perspective of front-line, treating physicians (see http://markajacobsonauthor.com/). In March, 2020, Dr. Jacobson was redeployed to Occupational Medicine division and in July, 2020, moved from the HIV/ID division to the Occupational Medicine, where he serves as the infectious diseases consultant for a team of MDs, NPs and RNs who manage employee COVID-19 health issues for all SF Department of Public Health facilities, including SF General Hospital. He currently staffs the Occupational Health Service COVID-19 and Vaccine Hotlines, has created and updates Hotline provider standard work guidance for testing/off-return to work decisions/management of COVID-19 vaccine adverse events, teaches Hotline providers, consults with Occupational Medicine leadership re policy changes and special issues that arise, and oversees a Vaccine Hotline, which he helped develop in December, 2020, for management of employees experiencing adverse effects of COVID-19 vaccination.
Education
Fellowship, 1986 - Infectious Diseases, University of California, Los Angeles
Internship/Residency, 1984 - Medicine, Kaiser Foundation Hospital, Oakland, CA
M.D., 1981 - Medicine, University of California, San Francisco
Honors and Awards
  • AIDS Research Institute Sarlo Award for Teaching Excellence, UCSF, 2013
  • Positive Health Program Teaching Award, UCSF, 2007
Websites
Publications
  1. Karbhari A, Mosessian S, Trivedi KH, Valla F, Jacobson M, Truty MJ, Patnam NG, Simeone DM, Zan E, Brennan T, Chen H, Kuo PH, Herrmann K, Goenka AH. Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol. 2023. PMID: 38011131


  2. Jacobson M, Hart C, Huen W, Suarez Guardado G, Villanueva A, Whitman J, Blanc PD. A Rapid Nucleic-Acid-Amplification-Test-Based, Conditional-Release-to-Work Policy for Health Care Personnel with Symptoms Consistent with COVID-19. 2022. PMID: 36240750


  3. Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. 2022. PMID: 35582785


  4. Jacobson MA, Zakaria A, Maung Z, Hart C, McCalmont T, Fassett M, Amerson E. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 SARS-CoV2 Vaccine (Moderna) in a Cohort of Hospital Employees. 2021. PMID: 34086881


  5. Maung Z, Kristensen M, Hoffman B, Jacobson MA. Temperature Screening of Healthcare Personnel is Ineffective in Controlling COVID-19. 2022. PMID: 35166255


  6. Quadri NS, Sultan A, Ali SI, Yousif M, Moussa A, Fawzy Abdo E, Hassany S, Kayandabila J, Benjamin A, Jacobson M, Ssebambulidde K, Ochola L, Ijeoma I, Debes JD. COVID-19 in Africa: Survey Analysis of Impact on Health-Care Workers. 2021. PMID: 33886500


  7. Presti RM, Handley SA, Droit L, Ghannoum M, Jacobson M, Shiboski CH, Webster-Cyriaque J, Brown T, Yin MT, Overton ET. Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status. 2018. PMID: 29851662


  8. Shiboski CH, Lee A, Chen H, Webster-Cyriaque J, Seaman T, Landovitz RJ, John M, Reilly N, Naini L, Palefsky J, Jacobson MA. Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy. 2016. PMID: 26919735


  9. Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson CA, Collier AC, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson MA. Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS. 2014. PMID: 24378728


  10. Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA. The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. 2013. PMID: 24260125


  11. Meyer AC, Jacobson M. Asymptomatic cryptococcemia in resource-limited settings. 2013. PMID: 23715897


  12. Jacobson M, Lurain N, Hunt P. Cytomegalovirus viraemia in the modern antiretroviral era(*). Volume 12 of Issue 7. 2011. PMID: 21729228


  13. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. Volume 203 of Issue 10. 2011. PMID: 21502083


  14. Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. 2009. PMID: 19632953


  15. Jacobson MA, Ditmer DP, Sinclair E, Martin JN, Deeks SG, Hunt P, Mocarski ES, Shiboski C. Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients. Volume 4 of Issue 4. 2009. PMID: 19381272


  16. Jacobson MA, Adler SP, Sinclair E, Black D, Smith A, Chu A, Moss RB, Wloch MK. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). 2009. PMID: 19168107


  17. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. Volume 49 of Issue 2. 2008. PMID: 18820536


  18. Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, Sinclair E. Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS. 2008. PMID: 18173357


  19. Sinclair E, Tan QX, Sharp M, Girling V, Poon C, Natta MV, Jabs DA, Inokuma M, Maecker HT, Bredt B, Jacobson MA. Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype. 2006. PMID: 17083038


  20. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Girling V, Adler SP. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. 2006. PMID: 16701925


  21. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. 2006. PMID: 16387547


  22. Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F. Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. 2005. PMID: 16306031


  23. Jabs DA, Holbrook JT, Van Natta ML, Clark R, Jacobson MA, Kempen JH, Murphy RL. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. 2005. PMID: 15878056


  24. Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. 2005. PMID: 16192248


  25. D'Amico R, Yang Y, Mildvan D, Evans SR, Schnizlein-Bick CT, Hafner R, Webb N, Basar M, Zackin R, Jacobson MA. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. 2005. PMID: 15821887


  26. Shacklett BL, Cox CA, Quigley MF, Kreis C, Stollman NH, Jacobson MA, Andersson J, Sandberg JK, Nixon DF. Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection. 2004. PMID: 15210827


  27. Sinclair E, Black D, Epling CL, Carvidi A, Josefowicz SZ, Bredt BM, Jacobson MA. CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals. 2004. PMID: 15357911


  28. Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC, Glesby MJ. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. 2003. PMID: 14673758


  29. Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF. Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection. 2003. PMID: 12719554


  30. Jacobson MA, Liu L, Khayam-Bashi H, Deeks SG, Hecht FM, Kahn J. Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. 2003. PMID: 12660541


  31. Jacobson MA, Khayam-Bashi H, Martin JN, Black D, Ng V. Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. 2002. PMID: 12473834


  32. Nokta MA, Holland F, De Gruttola V, Emery VC, Jacobson MA, Griffiths P, Pollard RB, Feinberg JE. Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease. 2002. PMID: 12085316


  33. Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, Fox L, Roe J, Kundu S, Pollard R. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. 2002. PMID: 12004273


  34. Jacobson MA, Schrier R, McCune JM, Torriani FJ, Holland GN, O'Donnell JJ, Freeman WR, Bredt BM. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. 2001. PMID: 11294673


  35. Chin-Hong PV, Sutton DA, Roemer M, Jacobson MA, Aberg JA. Invasive fungal sinusitis and meningitis due to Arthrographis kalrae in a patient with AIDS. 2001. PMID: 11158158


  36. Angel JB, Jacobson MA, Skolnik PR, Giordano M, Shapiro L, LeBeaut A, Greaves W, Fuchs AC. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. 2000. PMID: 11101061


  37. Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R, Tsunoda S, Gambertoglio JG. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. 1999. PMID: 10096579


  38. Jacobson MA, Wilson S, Stanley H, Holtzer C, Cherrington J, Safrin S. Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS. 1999. PMID: 10194072


  39. Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune JM. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. 1998. PMID: 9701250


  40. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, Hardy WD, Polis MA, Deutsch TA, Feinberg J, Spector SA, Walmsley S, Drew WL, Powderly WG, Griffiths PD, Benson CA, Kessler HA. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. 1998. PMID: 9588429


  41. Jacobson MA. AIDS-related cytomegalovirus retinitis. 1998. PMID: 15010704


  42. Feinberg JE, Hurwitz S, Cooper D, Sattler FR, MacGregor RR, Powderly W, Holland GN, Griffiths PD, Pollard RB, Youle M, Gill MJ, Holland FJ, Power ME, Owens S, Coakley D, Fry J, Jacobson MA. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study G 1998. PMID: 9419169


  43. Fredricks DN, Rojanasthien N, Jacobson MA. AIDS-related disseminated histoplasmosis in San Francisco, California. 1997. PMID: 9392979


  44. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, Owens S, Pollard R. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. 1997. PMID: 9164318


  45. Mueller AJ, Jacobson MA, Hurwitz S, Chuang EL, Friedberg DN, Haidt SJ, Heinemann MH, Jabs DA, Kaplan HJ, Freeman WR. Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovir. 1997. PMID: 9147441


  46. Marra CM, Gary DW, Kuypers J, Jacobson MA. Diagnosis of neurosyphilis in patients infected with human immunodeficiency virus type 1. 1996. PMID: 8655999


  47. Harb GE, Mandema JW, Delahunty T, Benowitz NB, Coleman R, Sheiner LB, Jacobson MA. Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection. 1996. PMID: 8537676


  48. Jacobson MA, De Gruttola V, Reddy M, Arduino JM, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. 1995. PMID: 7546418


  49. Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, Jacobson MA. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. 1995. PMID: 7712668


  50. Flexner C, van der Horst C, Jacobson MA, Powderly W, Duncanson F, Ganes D, Barditch-Crovo PA, Petty BG, Baron PA, Armstrong D. Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. 1994. PMID: 7995977


  51. Jacobson MA, Gallant J, Wang LH, Coakley D, Weller S, Gary D, Squires L, Smiley ML, Blum MR, Feinberg J. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. 1994. PMID: 7979285


  52. Jacobson MA, Kramer F, Bassiakos Y, Hooton T, Polsky B, Geheb H, O'Donnell JJ, Walker JD, Korvick JA, van der Horst C. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. 1994. PMID: 8014496


  53. Jacobson MA, Polsky B, Causey D, Davis R, Tong W, O'Donnell JJ, Kuppermann BD, Heinemann MH, Feinberg J, Lizak P. Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis. 1994. PMID: 8067763


  54. Stanley HD, Charlebois E, Harb G, Jacobson MA. Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease. 1994. PMID: 8106966


  55. Chin DP, Hopewell PC, Yajko DM, Vittinghoff E, Horsburgh CR, Hadley WK, Stone EN, Nassos PS, Ostroff SM, Jacobson MA. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. 1994. PMID: 7906290


  56. Jacobson MA, Causey D, Polsky B, Hardy D, Chown M, Davis R, O'Donnell JJ, Kuppermann BD, Heinemann MH, Holland GN. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. 1993. PMID: 8393058


  57. Jacobson MA, Yajko D, Northfelt D, Charlebois E, Gary D, Brosgart C, Sanders CA, Hadley WK. Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. 1993. PMID: 8515098


  58. Dyner TS, Lang W, Geaga J, Golub A, Stites D, Winger E, Galmarini M, Masterson J, Jacobson MA. An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. 1993. PMID: 8097787


  59. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. 1992. PMID: 1453334


  60. Reddy MM, Grieco MH, McKinley GF, Causey DM, van der Horst CM, Parenti DM, Hooton TM, Davis RB, Jacobson MA. Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. 1992. PMID: 1323624


  61. Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Deyton L. Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. 1992. PMID: 1346413


  62. Bacchetti P, Moss AR, Andrews JC, Jacobson MA. Early predictors of survival in symptomatic HIV-infected persons treated with high-dose zidovudine. 1992. PMID: 1535375


  63. Jacobson MA. Review of the toxicities of foscarnet. 1992. PMID: 1534839


  64. Jacobson MA, Hopewell PC, Yajko DM, Hadley WK, Lazarus E, Mohanty PK, Modin GW, Feigal DW, Cusick PS, Sande MA. Natural history of disseminated Mycobacterium avium complex infection in AIDS. 1991. PMID: 1682396


  65. Jacobson MA, Mills J, Rush J, Peiperl L, Seru V, Mohanty PK, Hopewell PC, Hadley WK, Broadus VC, Leoung G. Morbidity and mortality of patients with AIDS and first-episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infection. 1991. PMID: 1648316


  66. Jacobson MA, Drew WL, Feinberg J, O'Donnell JJ, Whitmore PV, Miner RD, Parenti D. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. 1991. PMID: 1645385


  67. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. 1991. PMID: 1827127


  68. Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, Valainis GT, Mildvan D, Abrams D, Wilber J. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. 1991. PMID: 1671651


  69. Wilcox CM, Diehl DL, Cello JP, Margaretten W, Jacobson MA. Cytomegalovirus esophagitis in patients with AIDS. A clinical, endoscopic, and pathologic correlation. 1990. PMID: 2169217


  70. Wilcox CM, Byford BA, Forsmark CE, Hadley WK, Cello JP, Jacobson MA. Campylobacter-like organisms are uncommon pathogens in patients infected with the human immunodeficiency virus. 1990. PMID: 2229366


  71. Leoung GS, Feigal DW, Montgomery AB, Corkery K, Wardlaw L, Adams M, Busch D, Gordon S, Jacobson MA, Volberding PA. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. 1990. PMID: 1975426


  72. Farese RV, Schambelan M, Hollander H, Stringari S, Jacobson MA. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. 1990. PMID: 2160217


  73. Jacobson MA, Peiperl L, Volberding PA, Porteous D, Toy PT, Feigal D. Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome. 1990. PMID: 2305441


  74. Jacobson MA, Abrams DI, Volberding PA, Bacchetti P, Wilber J, Chaisson RE, Crowe S, Howard W, Moss A. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. 1989. PMID: 2566637


  75. O'Donnell JJ, Jacobson MA. Cotton-wool spots and cytomegalovirus retinitis in AIDS. 1989. PMID: 2541095


  76. Jacobson MA, McGrath MS, Joseph P, Molaghan JB, Tadepalli S, Quinn R. Zidovudine-induced fever. 1989. PMID: 2666640


  77. Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N, Mills J. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. 1988. PMID: 2844921


  78. Jacobson MA, Mills J, Rush J, O'Donnell JJ, Miller RG, Greco C, Gonzales MF. Failure of antiviral therapy for acquired immunodeficiency syndrome-related cytomegalovirus myelitis. 1988. PMID: 2845899


  79. Jacobson MA, de Miranda P, Gordon SM, Blum MR, Volberding P, Mills J. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. 1988. PMID: 3261316


  80. Jacobson MA, O'Donnell JJ, Brodie HR, Wofsy C, Mills J. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. 1988. PMID: 2844981


  81. Mills J, Jacobson MA, O'Donnell JJ, Cederberg D, Holland GN. Treatment of cytomegalovirus retinitis in patients with AIDS. 1988. PMID: 2847289


  82. Ng VL, Jacobson MA, Khayam-Bashi H, McGrath MS. Lymphoma in an HIV-positive man after disappearance of a paraprotein. 1988. PMID: 3259675


  83. Jacobson MA, de Miranda P, Cederberg DM, Burnette T, Cobb E, Brodie HR, Mills J. Human pharmacokinetics and tolerance of oral ganciclovir. 1987. PMID: 2820301